Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary

Background: Recent international, randomized, placebo-controlled clinical trials (SPRINT-2; RESPOND-2) demonstrated that the triple combination of peginterferon (PEG), ribavirin (RBV) and boceprevir (BOC) was more efficacious than the standard dual therapy of PEG and RBV in treatment of patients chr...

Descripción completa

Detalles Bibliográficos
Autores principales: Odhiambo, Raymond, Chhatwal, Jagpreet, Ferrante, Shannon Allen, El Khoury, Antoine, Elbasha, Elamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia Data Analytics, LLC 2013
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471397/
https://www.ncbi.nlm.nih.gov/pubmed/37664146
http://dx.doi.org/10.36469/9854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471397/
https://www.ncbi.nlm.nih.gov/pubmed/37664146
http://dx.doi.org/10.36469/9854

Ejemplares similares